181 related articles for article (PubMed ID: 24242992)
1. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan.
Chen TC; Chen LC; Huang YB; Chang CS
Int J Clin Pharm; 2014 Feb; 36(1):172-81. PubMed ID: 24242992
[TBL] [Abstract][Full Text] [Related]
2. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.
Chen LC; Chen TC; Huang YB; Chang CS
Int J Clin Pharm; 2014 Feb; 36(1):120-7. PubMed ID: 24154825
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
[TBL] [Abstract][Full Text] [Related]
4. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Marin D; Bazeos A; Mahon FX; Eliasson L; Milojkovic D; Bua M; Apperley JF; Szydlo R; Desai R; Kozlowski K; Paliompeis C; Latham V; Foroni L; Molimard M; Reid A; Rezvani K; de Lavallade H; Guallar C; Goldman J; Khorashad JS
J Clin Oncol; 2010 May; 28(14):2381-8. PubMed ID: 20385986
[TBL] [Abstract][Full Text] [Related]
5. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
6. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
7. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
[TBL] [Abstract][Full Text] [Related]
8. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
Efficace F; Baccarani M; Rosti G; Cottone F; Castagnetti F; Breccia M; Alimena G; Iurlo A; Rossi AR; Pardini S; Gherlinzoni F; Salvucci M; Tiribelli M; Vignetti M; Mandelli F
Br J Cancer; 2012 Sep; 107(6):904-9. PubMed ID: 22871884
[TBL] [Abstract][Full Text] [Related]
9. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
10. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
Wang L; Pearson K; Ferguson JE; Clark RE
Br J Haematol; 2003 Mar; 120(6):990-9. PubMed ID: 12648069
[TBL] [Abstract][Full Text] [Related]
11. Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil.
Rego MN; Metze K; Lorand-Metze I
Clinics (Sao Paulo); 2015 May; 70(5):322-5. PubMed ID: 26039947
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM
Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227
[TBL] [Abstract][Full Text] [Related]
13. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
14. Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
Medhi K; Raina V; Kumar L; Sharma A; Bakhshi S; Gupta R; Kumar R
Leuk Lymphoma; 2010 Oct; 51(10):1850-4. PubMed ID: 20849386
[TBL] [Abstract][Full Text] [Related]
15. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.
Etienne G; Dulucq S; Nicolini FE; Morisset S; Fort MP; Schmitt A; Etienne M; Hayette S; Lippert E; Bureau C; Tigaud I; Adiko D; Marit G; Reiffers J; Mahon FX
Haematologica; 2014 Mar; 99(3):458-64. PubMed ID: 24362549
[TBL] [Abstract][Full Text] [Related]
16. Cultural factors related to adherence to imatinib in CML: a Mexican perspective.
Cantú-Rodríguez OG; Sánchez-Cárdenas M; Gutiérrez-Aguirre CH; Jaime-Pérez JC; Mancias-Guerra C; González-Llano O; Gómez-Almaguer D
Hematology; 2015 Mar; 20(2):72-6. PubMed ID: 25034734
[TBL] [Abstract][Full Text] [Related]
17. Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response.
Santoleri F; Lasala R; Ranucci E; La Barba G; Di Lorenzo R; Vetrò A; Di Bartolomeo P; Costantini A
Acta Haematol; 2016; 136(1):45-51. PubMed ID: 27160310
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
